碳酸钙D3联合重组人生长激素对特发性矮小症患儿临床效果

Clinical effect of calcium carbonate D3 combined with recombinant human growth hormone on idiopathic short-stature children

目的:研究分析碳酸钙D3联合重组人生长激素治疗特发性矮小症患儿的临床效果。方法:选取2023年1月至2024年1月我院66例特发性矮小症患儿,随机分为观察组和对照组(n=33)。对照组皮下注射重组人生长激素0.1IU•kg-1治疗,观察组在此基础上联合碳酸钙D3口服14mg•kg-1治疗。持续治疗1y,进行身高测量,并通过X线检查评估骨龄成熟程度,采用酶联免疫吸附法检测生长因子水平等指标。结果:治疗后,观察组身高、生长速度及身高标准差均优于对照组(P<0.05);观察组骨龄指数及骨龄年龄差均优于对照组(P<0.05);观察组生长因子水平高于对照组(P<0.05);两组治疗期间不良反应发生率无显著差异(P>0.05)。结论:碳酸钙D3联合重组人生长激素有效提升特发性矮小症患儿的钙质水平、骨骼成熟度及生长因子水平,促进生长发育。

Objective:To analyze the clinical effect of calcium carbonate D3 combined with recombinant human growth hormone in children with idiopathic short stature.Method:From January 2023 to January 2024,66 children with idiopathic short stature in our hospital were randomly divided into the observation group and the control group(n=33).The control group was treated with subcutaneous injection of recombinant human growth hormone 0.1 IU•kg-1,and the observation group was treated with calcium carbonate D3 orally at 14 mg•kg-1.After continuous treatment for 1 year,height was measured,bone age maturity was evaluated by X-ray examination,and growth factor level was detected by enzyme-linked immunosorbent assay.Results:After treatment,the height,growth rate,and height standard deviation of the observation group were better than those of the control group(P<0.05).The bone age index and bone age difference in the observation group were better than those in the control group(P<0.05).The level of growth factors in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Calcium carbonate D3 combined with recombinant human growth hormone can effectively improve the calcium level,bone maturity,and growth factor levels in children with idiopathic short stature,promoting growth and development.